Skip to main content
TipRanks
Go Ultimate75% OFF

NanoSphere Health Sciences Inc (NSHS.X) AI Stock Analysis

1 Followers
TSE:NSHS.X

NanoSphere Health Sciences Inc

(CNQX:NSHS.X)

Select Model
Rating:38Underperform
Price Target:CAD 0.02â–¼(-4.00% Downside)
Action:reiterated
Date:10/24/26

Severe financial weakness is the primary factor, reinforced by bearish technical momentum and an unfavorable loss-based valuation. The weighted score is 38.25, rounded to 38.

Positive Factors
Lower Cash BurnCash outflows narrowed from 2022–2025 versus earlier years, indicating some improvement in burn control. If maintained, this could extend financial runway and give management more time to pursue commercialization, although cash generation remains negative.
Negative Factors
No Revenue BaseNo reported revenue indicates that the company remains pre-commercial or inactive on the top line, leaving no demonstrated sales engine to fund operations. Without revenue traction, future progress depends heavily on commercialization and the ability to secure additional financing.

NanoSphere Health Sciences Inc (NSHS.X) vs. iShares MSCI Canada ETF (EWC)

-20%-10%0%10%20%30%TSE:NSHS.X0.00%EWC+18.67%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 205.50K
Dividend Yield
―
Average Volume (3M)
5,916
Price to Earnings (P/E)
-1.8
Beta (1Y)
-2.66
Revenue Growth
―
EPS Growth
-132.14%
Country
Canada
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

NanoSphere Health Sciences Inc Business Overview & Revenue Model

Company Description

NanoSphere Health Sciences Inc. is a nano-biotechnology enterprise operating in the United States and Canada, specializing in the provision of biologically active compounds. The company's primary offering is the NanoSphere Delivery System, an innovat...

NanoSphere Health Sciences Inc Financial Statement Overview

Summary

No revenue, persistent net losses, deeply negative equity, minimal assets, and ongoing cash burn indicate severe financial distress despite low debt and slightly improving losses.

Income Statement

5Very Negative

Balance Sheet

8Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-213.44K-181.91K-251.59K-319.60K-286.00K-341.00K
Net Income-83.07K-86.27K―-228.13K-282.00K-356.00K
Balance Sheet
Total Assets16.81K16.81K13.59K17.97K60.05K132.51K
Cash, Cash Equivalents and Short-Term Investments1,8821,8822,0229,31655.01K130.76K
Total Debt57.14K57.14K30.71K000
Total Liabilities1.37M1.37M1.23M1.57M1.37M1.21M
Stockholders Equity-1.35M-1.35M-1.22M-1.56M-1.31M-1.08M
Cash Flow
Free Cash Flow-24.33K-23.38K-35.92K-53.70K-67.66K-64.68K
Operating Cash Flow-24.33K-23.38K-35.92K-53.70K-67.66K-64.68K
Investing Cash Flow000000
Financing Cash Flow26.57K27.00K28.83K00182.43K

NanoSphere Health Sciences Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:NSHS.X against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VXLTSE:VXL43NeutralCAD 458.16K1.1534.52%―――
TSE:NSHS.XTSE:NSHS.X38UnderperformCAD 256.88K-1.766.14%――-132.14%
TSE:CHGXTSE:CHGX24UnderperformCAD 415.65K-0.2319.40%―――

* Healthcare Sector Average

Performance Comparison

0%50%TSE:NSHS.XTSE:ABRTTSE:VXLTSE:CHGXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:NSHS.X and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:NSHS.XNanosphere Health Sciences0.030.000.00%
TSE:ABRTAlbert Labs International Corp.0.010.000.00%
TSE:VXLVaxil Bio0.12-0.03-23.33%
TSE:CHGXChitogenx Inc.0.010.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026